Spinal Cord Stimulator Explant and Revision Complicated by Syrinx Formation: A Case Report and Literature Review.

Spinal cord stimulation (SCS) has been shown to be a safe, effective, and drug-free treatment option for many chronic pain conditions including refractory low back pain. The most commonly reported complication of SCS is equipment failure. We report a case of spinal cord injury (SCI) during SCS explant and revision. This 61-year-old female veteran complained of intermittent shock-like sensations 3-4 times a week for three months prior to her clinic visit. The device was initially implanted in 2009 secondary to neurogenic claudication with appropriate relief. The battery was replaced in 2015. Pain Management Service referred the patient to neurosurgery for replacement of the original SCS unit. Immediately following surgery she complained of severe left lower extremity pain concentrated in the medial thigh radiating into the groin and buttock. She also complained of pain, weakness and numbness in both legs (left more than right). Magnetic resonance imaging (MRI) revealed an edematous area in the left spinal cord between T11-T12. The patient was placed on steroids, ketamine infusion for pain control, and MRI the next day showed slight improvement of the edema and she was discharged home. Follow-up MRI two months later revealed mild diminution in the size of the cord edema. Her pre-operative shock-like sensations had not returned. While rare, spinal cord injury can occur and should be identified and managed expeditiously. Our case here reports for the first time an association between SCS explant/revision and syrinx formation.

Further Evidence that Onabotulinum Toxin is a Viable Treatment Option for Pediatric Chronic Migraine Patients.

Introduction Chronic migraine is particularly devastating. It affects school work, extracurricular activities, and quality of life, including relationships with other family members, and can also influence the mental health of both the migraineurs and family members. According to the International Classification of Headache Disorders, 3rd edition (ICHD-3), chronic migraine is defined as 15 or more headache days per month for greater than three months, where at least on eight days per month, there are features of migraine headache. Although botulinum toxin type A (BoNTA) has been proven effective for treating chronic migraine in adults, little literature exists about its use in children. Here, we present the treatment response in children with chronic migraines treated with BoNTA at our institutions Duke and State University of New York (SUNY) Upstate. Method A retrospective analysis of 30 adolescent migraineurs who met ICHD-3 criteria for chronic migraine were treated with BoNTA injection according to the standardized adult protocol. Descriptive statistics and paired t-tests were performed. A total of 185 units of botulinum toxin were injected intramuscularly per patient, as in addition to the standard 31 sites for a total of 155 units, an additional 30 units were given in areas that were felt to provide further benefit. Results Participants (n=30) were 16.5 ± 1.83 years old. The headaches were precipitated by trauma in seven cases. All had failed standard pharmacotherapy, including amitriptyline and topiramate. An average of 2.47 ± 1.6 BoNTA injection cycles was performed. Migraine severity decreased significantly from 7.47 ± 1.89 on a 10-point scale to 4.34 ± 3.02 (p<.001). Additionally, headache frequency improved from 24.4 ± 7.49 painful days per month to 14.8 ± 12.52 painful days per month (p<.001). One patient developed nausea related to injections; all others tolerated it well, with no side effects. Discussion BoNTA injection was a safe and effective therapy for chronic migraine in our cohort of children recalcitrant to medical therapy. Further research with multi-centered, double-blinded, randomized, placebo-controlled trials is warranted to evaluate the long-term safety and efficacy in this population.

Iatrogenic Spinal Epidural Hematoma Associated with Intracranial Hypotension.

Epidural steroid injections (ESIs) are one of the few modalities currently in use for treating chronic spinal pain. There are two approaches: interlaminar ESIs and transforaminal ESIs. Complications arising from either approach are rare, but one such complication is cerebrospinal fluid (CSF) leak leading to intracranial hypotension. Even rarer is the development of iatrogenic spinal epidural hematoma in the context of the injections. Interestingly, an association with intracranial hypotension and spinal epidural hematoma has yet to be established. Even the characteristics of an iatrogenic spinal epidural hematoma are not well defined as there are different theories of how this develops and whether we are dealing with arterial or venous blood. Our case is unique as it appears our patient had developed not one, but both clinical symptoms supportive of intracranial hypotension from a CSF leak induced iatrogenically from a cervical epidural injection and imaging demonstrated thoracic-level spinal epidural hematoma. It is unclear whether the injection directly led to the spinal leak causing the intracranial hypotension, which then brought on the formation of the hematoma or if the injection led to both intracranial hypotension and hematoma formation independent of each other. From a clinical practice standpoint, given our case suggests the hematoma was concomitantly associated with intracranial hypotension, and the possibility exists that the hematoma may have formed in the context of the intracranial hypotension, then targeted blood patches may need to be done with greater urgency to preventing hematoma formation. Further studies are needed involving clotting factors comparing arterial and venous blood. It is also puzzling why the epidural blood from the hematoma did not clot the leak. This concomitancy deserves further attention and may lead to changes in how we manage cervical epidural injection patients who are found to have CSF leak and a spinal epidural hematoma.

Use of Digital Infrared Thermal Imaging in the Electromyography Clinic: A Case Series.

INTRODUCTION: Foot drop often results from denervation of the dorsiflexor muscles in the leg. Neurological evaluation begins with lower extremity motor testing followed by electromyography needle electrode examination (EMG-NEE). We explored digital infrared thermography (IRT) as a complementary tool in diagnosing peripheral nerve disorders. METHODS: Using a digital IRT camera, we recorded differences in skin surface temperatures from affected and unaffected limbs in three patients with unilateral foot drop. Denervation in the affected limb was confirmed with EMG-NEE. RESULTS: IRT imaging revealed lower relative skin surface temperatures in regions of the leg corresponding to denervated dorsiflexor muscles for all three consecutive patients who presented to the EMG Clinic with foot drop.  Conclusions: Denervation appears to cause a decrease in thermal energy output from affected muscle groups. Alongside the EMG and magnetic resonance imaging (MRI), IRT may have an important role in assessing the severity and prognosis of a nerve injury. This observation may have implications for chronic pain syndromes, such as complex regional pain syndrome (CRPS), in which thermal change is a diagnostic criterion.